Search

Etanautine

Gramicidin D

Gramcidins are 15 residue peptides with alternating D and L amino acids, which assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix. … Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus

Cefotetan

The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

Aleglitazar

Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects

Diprenorphine

A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]

Batroxobin

In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. … Once bound to fibrin, it will cause fibrin accretion(clot formation) to a degree 18 folds greater than thrombin.

Sesame oil

Sesame oil is reported to possess antioxidant, antiaging, antihypertensive, immunoregulatory and anticancer properties. It has also shown to accelerate alcohol decomposition in the liver [A27257]. … Sesame oil is considered an indirect additive used in food cotact substances by the FDA.

Phosphate ion

Diosmetin

Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231]. … Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflamatory activities [A27231]. It also acts as a weak TrkB receptor agonist [A27230].

Midostaurin

It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.